16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
19:21 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Fragile X syndrome Mouse studies suggest inhibiting the eIF4E-eIF4G1 interaction could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a tool compound that inhibits the eIF4E-eIF4G1 interaction increased dendritic spine...
18:36 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1-MKNK2-eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1 or MKNK2 decreased mechanical hyperalgesia,...
02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Eukaryotic translation initiation factor 4E binding protein 1 (eIF4EBP1)

Endocrine/metabolic disease INDICATION: Obesity Mouse studies suggest promoting eIF4EBP1 expression could help treat obesity. In mice fed a high-fat diet, transgenic expression of human eIF4EBP1 decreased body weight, serum levels of leptin, triglycerides and IL-6, fasting blood...
07:00 , Aug 15, 2016 |  BioCentury  |  Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
07:00 , Mar 24, 2016 |  BC Innovations  |  Strategy

Combo platter

In the last few years, Incyte Corp. has changed its strategy to incorporate combination options into the design and selection of its NCEs from the start. The company has developed an approach to target independent...